化疗联合安罗替尼在晚期胰腺癌中的观察分析  

Efficacy of chemotherapy combined with anlotinib against advanced pancreatic cancer

作　　者：徐宝余 沈华 李歆[1] 韩峰 XU Baoyu;SHEN Hua;LI Xin;HAN Feng(School of Pharmacy,Nanjing Medical University,Nanjing Jiangsu 211166,China;Depar-tment of Human Anatomy,School of Basic Medical Sciences,Nanjing Medical University,Nanjing Jiangsu 211166,China;Sir Run Run Hospital,Nanjing Medical University,Nanjing Jingsu 211166,China)

机构地区：[1]南京医科大学药学院,江苏南京211166 [2]南京医科大学基础医学院人体解剖学系,江苏南京211166 [3]南京医科大学附属逸夫医院,江苏南京211166

出　　处：《中国药物警戒》2022年第1期72-73,86,共3页Chinese Journal of Pharmacovigilance

基　　金：国家自然科学基金资助项目(72074123,716731471);江苏省政策引导类计划(软科学研究)(BR2020043);吴阶平医学基金会临床科研专项资助基金(320.6750.2020-10-74)。

摘　　要：目的研究化疗联合抗血管生成药物在晚期胰腺癌中的疗效。方法回顾性分析2019年10月31日至2021年2月28日南京医科大学附属逸夫医院及海安市人民医院肿瘤科治疗的60例晚期胰腺癌患者,按照患者的不同治疗方案分为试验组和对照组,每组各30例。对照组给予单药吉西他滨治疗,试验组给予白蛋白结合型紫杉醇与吉西他滨作为主化疗联合安罗替尼治疗。比较2组患者的生存情况及主要不良反应情况。结果化疗联合安罗替尼治疗能够延长晚期胰腺癌患者的生存时间。结论化疗联合安罗替尼可提高晚期胰腺癌的疗效,为临床治疗晚期胰腺病提供参考。Objective To investigate the efficacy of chemotherapy combined with anlotinib in treating advanced pancreatic cancer.Methods The clinical data on 60 patients with advanced pancreatic cancer was retrospectively analyzed who had been treated at Yifu Hospital and Hai’an People’s Hospital between October 31,2019 and February 28,2021.The patients were divided into a control group and a test group using the random number table method,with 30 in each group.Patients in the control group were treated with single-agent gemcitabine while those in the experimental group were treated with albumin-bound paclitaxel and gemcitabine as the main chemotherapy combined with anlotinib.The overall survival and incidence of adverse reactions were observed.Results Chemotherapy combined with anlotinib prolonged the survival of patients with advanced pancreatic cancer.Conclusion Chemotherapy combined with anlotinib can improve the therapeutic effect against advanced pancreatic cancer.

关 键 词：胰腺癌 吉西他滨 白蛋白结合型紫杉醇 安罗替尼 

分 类 号：R994.11[医药卫生—毒理学]